The history of copyright's flagship drug presents a interesting case for investors in the drug sector. While initially a phenomenal success, producing vast sums, the intellectual property end and the subsequent flood of cheaper versions have drastically impacted earnings. This presents questions about the ongoing viability of similar drug develo… Read More